AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06220305 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: DNA methylation joint AI imaging
Description: DNA were extracted from patients'plasma ,then the DNA was bisulfite converted and tested by DNA methylation assay.The results were combined with AI images to differentiate between benign and malignant lung nodules.
Study NCT05467293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.3% YP-P10 Ophthalmic Solution
Description: Drug: YP-P10 Ophthalmic Solution
Study NCT05467293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% YP-P10 Ophthalmic Solution
Description: Drug: YP-P10 Ophthalmic Solution
Study NCT05467293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: YP-P10 Placebo Ophthalmic Solution (vehicle)
Description: Placebo YP-P10 Placebo Ophthalmic Solution (vehicle)
Study NCT06404619 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education program
Description: The message emphasizes the importance of quality of life and positive psychology. The concept of quality of life is described as multidimensional, also the message highlights the steps to change one's lifestyle, including self-reflection, habit modification, and commitment to a comprehensive lifestyle change include importance of physical activity, management of stress, quality and quantity of sleep and specific recommendations are provided regarding drinking water, organizing meals, and adopting a healthy balanced diet with attention to portion sizes. The message also discussed fitness foods that aid digestion and promote a healthy body. The message introduced the Healthy Eating Plate.
Study NCT06404619 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education program
Description: The message emphasizes the importance of quality of life and positive psychology. The concept of quality of life is described as multidimensional, also the message highlights the steps to change one's lifestyle, including self-reflection, habit modification, and commitment to a comprehensive lifestyle change include importance of physical activity, management of stress, quality and quantity of sleep and specific recommendations are provided regarding drinking water, organizing meals, and adopting a healthy balanced diet with attention to portion sizes. The message also discussed fitness foods that aid digestion and promote a healthy body. The message introduced the Healthy Eating Plate.
Study NCT05828316 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience-based intervention
Description: resilience-based intervention is a curriculum that offers a careful selection of evidence-based exercises to build coping skills and promote thriving. The resilience-based intervention philosophy is that there are many routes to achieving greater resiliency. Each participants choose from a menu of exercises in the areas of goal-setting, emotional skills, social connection, health, meaning, and self-talk. The ability to choose exercises that fit their specific goals, interests, and schedules is important, because the most effective strategies are the ones that people actually do, which tend to be the ones that are most enjoyable and personally relevant. No single practice is going to work for everyone regardless of its proven benefits. resilience-based intervention makes improving well-being accessible, manageable and fun, by introducing a variety of bite-sized, exercises that participants can experiment with and find what works for them.
Study NCT04396249 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tVNS
Description: One electrode tip is used as their common terminal, and the other two electrode tips are respectively connected to the skin surfaces of the auricle and the external auditory meatus. Each subject will have 10 active tVNS sessions.The active tVNS group will be stimulated with a 2 mA current for 30 minutes.
Study NCT04396249 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tVNS
Description: Each subject will have 10 sham tVNS sessions.The sham tVNS group will be stimulated with a 2 mA current for 30 minutes. Except for the stimulation site, other parameters are the same as active group.
Study NCT06116747 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Support for fathers of preterm infants
Study NCT06161207 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Indocyanine Green Tracer Using in 3D plus Ultra High Resolution Laparoscopic Gastrectomy with Lymph Node Dissection
Description: Indocyanine green tracer is used with 3D plus ultra high resolution laparoscopic gastrectomy with lymph node Dissection for gastric cancer
Study NCT06161207 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Indocyanine Green Tracer Using in 3D plus Ultra High Resolution Laparoscopic Gastrectomy with Lymph Node Dissection
Description: Indocyanine green tracer is used with 3D plus ultra high resolution laparoscopic gastrectomy with lymph node Dissection for gastric cancer
Study NCT06359262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hope@School
Description: A digital platform aimed at promoting student mental health in schools
Study NCT06359262 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Regular student health care in schools
Study NCT05686863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Remazolam for sedation in children undergoing bidirectional endoscopy
Study NCT05686863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esketamine
Description: Esketamine
Study NCT05686863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Esketamine
Study NCT05686863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol
Study NCT05686863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil
Description: remifentanil
Study NCT05686863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil
Description: remifentanil
Study NCT03612466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 153Sm-DOTMP
Description: For Levels 1- 3, the Day 1 dosages will be the same (0.5 millicurie (mCi)/kg 153Sm-DOTMP) for all levels but the Day 8 dosages will be 0.5, 1.0 and 3.0 mCi/kg respectively. For Levels 4, 5 \& 6, the Day 1 dosages will be the same (0.5 mCi/kg 153Sm-DOTMP) for all levels but the Day 8 dosages will be 3, 6, then 10 mCi/kg 153Sm-DOTMP respectively.
Study NCT03612466 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy.
Description: The amount of radiation will be determined based on how much radiation was delivered to each tumor by the 153Sm-DOTMP, and will be targeted to 70 Gray (Gy)
Study NCT03612466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Description: Calcium carbonate will be given to participants as prophylaxis against hypocalcemia..
Study NCT03612466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mozobil
Description: Participants who require stem cell collection will be given Mozobil to help mobilize hematopoietic stem cells into the circulation for collection.
Study NCT03612466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neupogen Injectable Product
Description: Participants who require stem cell collection will be given Neupogen to help mobilize hematopoietic stem cells into the circulation for collection.
Study NCT05874102 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sidelying
Description: Position sidelying then Upright
Study NCT05874102 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Upright
Description: Position upright then sidelying
Study NCT05418439 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Drink Poppi Soda
Description: Drink Poppi Vinager Soda
Study NCT05554640 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acuvue® Oasys MAX 1-Day
Description: TEST Lens
Study NCT05554640 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dailies Total 1
Description: CONTROL Lens
Study NCT05361564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: After 7-day lead-in 90mg/day, brigatinib 180mg/day from 4 to 10weeks(optimal duration: 6 weeks)
Study NCT05917652 — intervention group
Intervention type: BEHAVIORAL
Intervention: Tool kit
Description: The study team will develop and design key elements of the implementation intervention (toolkit) among a small group of burn and non-burn clinician stakeholders (4-6 total). The study team will use in-person interviews with stakeholders and a semi-structured interview guide to elicit feedback and assess face and content validity of the toolkit elements prior to deployment across the study hospitals. For those who consent to participation, the study team will conduct virtual teleconference interviews in-person using a secure videoconferencing platform while the person is not working, at a time convenient for them. Interviews will last between 45 and 60 minutes. The study team anticipates conducting 4-6 interviews to finalize toolkit elements prior to implementation.
Study NCT04773743 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Remotely delivered yoga intervention
Study NCT04848389 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin Adhesive procedure
Description: The scar is closed in 2 planes. The subcutaneous plane is closed with an absorbable 3/0 vicryl-type thread, the cutaneous plane is closed by applying skin adhesive. A drying time of 25 seconds is necessary to obtain a satisfactory seal.
Study NCT04848389 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard suture procedure
Description: The scar is closed in 2 planes. The subcutaneous plane is closed with an absorbable thread of the 3/0 Vicryl-type, the cutaneous plane is closed with the same thread with an subcutaneous stitch.
Study NCT05049577 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Analgesia/Nociception Index (ANI)
Description: V1 and V5 electrocardiographic positions as per the manufacturer's recommendations. The ANI was continuously recorded and displayed with a frequency of 1 Hz. ANI scores measured immediately before propofol administration, half-dose administration (1mg/kg), and full-dose administration (2mg/kg)of propofol.
Study NCT05049577 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Analgesia/Nociception Index (ANI)
Description: V1 and V5 electrocardiographic positions as per the manufacturer's recommendations. The ANI was continuously recorded and displayed with a frequency of 1 Hz. ANI scores measured immediately before propofol administration, half-dose administration (1mg/kg), and full-dose administration (2mg/kg)of propofol.
Study NCT05324670 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Didactic model for suicidal behavior in the framework of impulsivity and ideations
Description: It will be in the form of lectures (Educational approach). Content will be developed one day before the commencement of the session. The Knowledge provided in the form of written material with proper explanation shall not exceed 30 minutes and a Focused group Discussion will be held at the end of each month.
Study NCT05324670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Didactic model for suicidal behavior in the framework of impulsivity and ideations
Description: It will be in the form of lectures (Educational approach). Content will be developed one day before the commencement of the session. The Knowledge provided in the form of written material with proper explanation shall not exceed 30 minutes and a Focused group Discussion will be held at the end of each month.
Study NCT05422690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction Chemotherapy Triplet Therapy
Description: Gemcitabine 1000 mg/m2, Cisplatin 25 mg/m2 infused on both day 1 and day 8 of a 21-day cycle. Durvalumab 1500 mg will be given on day 1 of each cycle.
Study NCT05422690 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concurrent Y-90 treatment
Description: Patients will undergo a Y-90 treatment planning consultation by the treating interventional radiologist during cycle 1. One or two cycles (depending on tumor size) of cisplatin, 25 mg/m2 and gemcitabine 300 mg/m2 given on day 1 and day 8 in combination with Yttrium-90 (Y-90) microspheres which will be given on day 3-7 or day 10-21 at the discretion of the interventional radiologist, separated in time by at least 2 days from a chemo infusion during that cycle
Study NCT05422690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation Doublet Therapy:
Description: Gemcitabine 1000 mg/m2 and Cisplatin 25 mg/m2 given on days 1 and 8 of a 21-day cycle with durvalumab 1500 mg given on day 1 of each cycle for 3-5 additional cycles. For the cycle directly after Y-90, gemcitabine will be kept at a dose of 300 mg/m2 to minimize risk of toxicity.
Study NCT06318338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Program
Description: Study participants will be provided a HTC or Pico VR head-mounted device (HTC Flow, HTC Focus or Pico Neo Pro) which will be fitted for comfort. Patients will remain seated for the entirety of the VR program. The program generally takes about ten minutes to complete but may last up to 11 minutes. The program displays a relaxing environmental setting with narration based in mindfulness meditation principles. Subjects will be prompted to practice breathing exercises designed to relax and reduce anxiety.
Study NCT05994131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN10018
Description: orally taken once daily
Study NCT05994131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furmonertinib
Description: orally taken once daily
Study NCT05994131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib
Description: orally taken once daily
Study NCT04701346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low SAA diet
Description: Diet with low content of methionine and cysteine
Study NCT04701346 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High SAA diet
Description: Diet with high content of methionine and cysteine
Study NCT04914598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ENDOSTAR，cisplatin
Description: After sufficient puncture and drainage or drainage, use Endo® (45mg/time in thoracic cavity, 60mg/time in abdominal cavity) + cisplatin (40mg/time) intracavitary injection, administration on 1, 4, and 7 days, 3 times as a course of treatment
Study NCT04914598 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo , cisplatin
Description: Placebo , cisplatin
Study NCT04214496 — intervention group
Intervention type: DEVICE
Intervention: Sedline
Description: Intraoperative EEG monitorization
Study NCT05118620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active bupivacaine 0.375% PENG block
Description: A PENG block with bupivacaine 0.375% and epinephrine will be administered using ultrasound-guidance
Study NCT05118620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo normal saline PENG block
Description: A PENG block with normal saline and epinephrine will be administered using ultrasound-guidance
Study NCT06283953 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trach Plus
Description: The Trach Plus program includes education, social support, and outreach to outpatient care team.
Study NCT06283953 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Trach Me Home
Description: The Trach Me Home discharge program includes caregiver education, skills training and case management.
Study NCT06283953 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trach Me Home
Description: The Trach Me Home discharge program includes caregiver education, skills training and case management.
Study NCT04884100 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Validating and improving PPG-based algorithms
Description: Our project aims at validating and improving PPG-based algorithms that were previously developed during the time course of a preceding study mini-Holter, accepted by the CER-VD in 2015. The developed features might help improve our understanding of the physio-pathological expression of cardiac arrhythmias. Indeed, current evidence demonstrates that PPG signals contain rich information on diverse cardiovascular mechanisms and properties
Study NCT00730873 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure
Study NCT06305052 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk
Description: Premature newborns allocated to the intervention group will receive olfactory and taste stimuli immediately before feeding through an oral/nasal gastric tube.~In the intervention group, the taste stimulus will be carried out through a drop of milk administered directly to the tongue of the premature baby if he is awake, if the newborn is sleeping the milk will be placed on his lips.~The olfactory stimulus will be offered through a drop of milk using a cotton swab, positioned close to the premature baby's nostrils as close as possible without touching them, immediately before the tube diet.
Study NCT06305052 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: In the control group, the taste stimulus will be done through a drop of double-distilled water on a cotton swab, then administered directly to the tongue of the premature baby if he is awake, however, when he is sleeping, the drop of water will be deposited on his lips. The olfactory stimulus in the control group will be carried out with a drop of double-distilled water using a cotton swab, positioned close to the nostrils as close as possible without touching them, immediately before carrying out the tube diet.
Study NCT06383650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid
Description: Patients will undergo CT imaging with the use of contrast for diagnosis of BCVI. Patients will be monitored for feasibility outcomes, as well as the development of stroke and bleeding complications.
Study NCT05083845 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Same blocks with different local anesthetic volume
Description: Erector spinae plane block with different local anesthetic volumes will be applied to the patients under real-time ultrasound guidance.
Study NCT01882296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGSPT_10
Description: AGSPT 10mg for 7days administration
Study NCT01882296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGSPT_20
Description: AGSPT 20mg for 7days administration
Study NCT01882296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGSPT_40
Description: AGSPT 20mg x 2tablet for 7days administration
Study NCT01882296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole_20
Description: Pantoprazole 20mg for 7days administration
Study NCT01882296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole_40
Description: Pantoprazole 40mg for 7days administration
Study NCT05471388 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: serum asprosin
Description: assessment of serum asprosin by a commercially available double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) kit.
Study NCT01571141 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monogin
Description: Gynaecological solution with polyhexamethylene biguanide, pH 4.0
Study NCT05319496 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittently scanned continuous glucose monitor (isCGM)
Description: A wearable sensor the size of 2 stacked quarters, that allows individuals to scan their glucose levels on demand. No fingerstick is required. The device measure interstitial glucose through a filament that is inserted under the skin. The application process is painless, and each sensor lasts 90 days. Sensors can be scanned with certain smart phones. This device is marketed as the FreeStyle Libre 2 glucometer (Abbott Laboratories, IL).
Study NCT05319496 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education and coaching
Description: Two encounters with a certified diabetes educator, who will assess lifestyle and medications, and provide individualized advice on diet, physical activity, and medication changes to improve glycemic control.
Study NCT05319496 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and coaching
Description: Two encounters with a certified diabetes educator, who will assess lifestyle and medications, and provide individualized advice on diet, physical activity, and medication changes to improve glycemic control.
Study NCT04771013 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thymic peptides
Description: 250 mg oral daily dose of lyophilized thymic peptides dissolved in 50 mL of water, administered with an empty stomach.
Study NCT06203535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: In addition to the standard physical therapy exercise programme (which includes flexibility and balance exercises), twenty individuals with idiopathic chronic fatigue will participate in an aerobic training group and walk for 45 minutes on a treadmill three times a week for two months. The workouts began with a five- to ten-minute warm-up on the treadmill and concluded with an equally extended cool-down. Using the Karvonen method, for exercise intensities range from 60 to 75 percent of heart rate reserve during a 35-minute group cumulative exercise session.
Study NCT06455657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breast cancer education
Description: Questionnaires and scales will be administered to the participants as a pre-test. Breast cancer education will be provided in groups and their feedback will be received. Reminder training will be repeated 1 month after the training. The survey and scales will be administered to the participants as a posttest 1 month after the second training.